Yes, to some degree; it informs the risk/benefit ratio when I discuss adjuvant osimertinb with patients. The benefit of adjuvant osimertinib was seen in stages 1B, 2 and 3 but the magnitude of the benefit increased with higher stages. This makes sense because the risk of recurrence increases with in...

Benefits were seen in stages 1, 2, and 3 disease. Of course, the benefits were greater in stage 2 and 3; however, there was still clear significance in the stage 1 setting. I would use it in all.

I would only offer adjuvant osimertinib for resected stage IB-III cancers. When I am discussing the magnitude of benefit, I distinguish between stage IB and stage II-III cancers. A recommendation for stage IA patients would require a new study. The hazard ratios for disease free survival were 0.39,...

I agree with Drs. @Jonathan W. Goldman, @Helena A. Yu, and @Roy S. Herbst. While the magnitude of benefit was greater in II/III, I do offer treatment to Ib as well. Perhaps I have a lower threshold to adjust dose or stop if not well tolerated, though that is not usually an issue.

I agree with the previous comments and would offer to stage IB as well with the caveat that the likelihood of benefit may be smaller than the more advanced stage. It is worth noting that ADAURA enrolled stage IB as defined by AJCC 7, which included tumors 3.1-5.0 cm in the IB stage group. The hazard...